Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity

American Journal of Transplantation

Volumn 6, Issue 8, 2006, Pages 1963-1967

  Boger C A ^a   Rummele P ^a   Mihatsch, M J ^b   Banas, B ^a   Kramer B K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Calcineurin inhibitor toxicity; Doppler sonography; Histology; Immunosuppression; Kidney transplantation; Renal failure

Indexed keywords

CALCINEURIN INHIBITOR; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ACUTE TOXICITY; ADULT; ARTICLE; CADAVER DONOR; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DOPPLER FLOWMETRY; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY VASCULAR RESISTANCE; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROTOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RENOVASCULAR DISEASE; VASCULAR RESISTANCE;

EID: 33745778666     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01381.x     Document Type: Article

References (21)

1. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporin nephrotoxicity. Transplant Proc 1988; 20: 759-771.
2. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91: 2144-2149.
3. Colvin RB. Renal Transplant Pathology. Chapter 33. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstall's pathology of the kidney. Philadelphia, PA, USA: Lippincott-Raven; 1998: 1409-1540.
4. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
5. Kou R, Greif D, Michel T. Dephosphorylation of endothelial nitric oxide synthase by vascular endothelial growth factor. J Biol Chem 2002; 277: 29669-29673.
6. Karsdorp VHM, van Vugt JMG, van Geijn HP et al. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. Lancet 1994; 344: 1664-1668.
7. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732-736.
8. Heine GH, Girndt M, Sester U, Kohler H. No rise in renal Doppler resistance indices at peak serum levels of cyclosporin A in stable kidney transplant patients. Nephrol Dial Transplant 2003; 18: 1639-1643.
9. Di Palo FQ, Rivolta R, Elli A et al. Effect of cyclosporin A on renal cortical resistances measured by color Doppler flowmetry on renal grafts. Nephron 1993; 65: 240-244.
10. Weingart C, Leingaertner T, Bergler T, Krüger B, Böger CA, Mack M, Banas B, Krämer BK. Increase in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: a study in patients with stable renal allograft function. Int J Clin Pharmacol Ther 2006; in press.
11. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993; 17: 60-68.
12. Bagnis C, Deray G, Dubois M et al. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. Am J Nephrol 1997; 17: 17-24.
13. Morozumi K, Takeda A, Uchida K, Mihatsch MJ. CYA Nephrotoxicity: How does it affect renal allograft function and transplant morphology? Transplant Proc 2004; 36 (Suppl 2S): 251S-256S.
14. Radermacher J, Mengel M, Ellis S et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349: 115-124.
15. Mac Donald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
16. Kahan BD, The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194-201.
17. Eisen HJ, Tuzcu EM, Dorent R et al., RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
18. Banas B, Böger C, Krämer B. Everolimus in cardiac-transplant recipients. N Engl J Med 2003; 349: 2271-2272; author reply 2271-2272.
19. Vitko S, Margreiter R, Weimar W et al., RAD B201 Study Group. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532-1540.
20. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340.
21. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635.